Navigation Links
Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
Date:8/16/2010

RYE, N.Y., Aug. 16 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company will present at the Rodman & Renshaw Annual Global Investment Conference, scheduled for September 12-15 at the New York Palace Hotel in New York City.

Dr. Joan Fallon, Curemark's founder and CEO, will update investors on the progress of the company's clinical research for CM-AT, its autism treatment in development.  She will also discuss the Investigational New Drug (IND) authorization Curemark recently received from the FDA for CM – 4612 to treat attention deficit hyperactivity disorder (ADHD). The U.S. Food and Drug Administration (FDA) has given clearance to Curemark's Investigational New Drug (IND) application for a Phase III clinical trial for the use of CM – 4612 in the treatment of attention deficit hyperactivity disorder (ADHD).

"We are very happy to have this opportunity to present at the Rodman & Renshaw annual investment conference.  Curemark has achieved a variety of major milestones that we are looking forward to sharing with attendees," Fallon said.  

CM-AT, Curemark's autism treatment, addresses enzyme deficiencies in autistic children which affect the availability of amino acids, the building blocks of chemicals essential for brain function.  Phase III clinical trials are underway at 13 sites nationwide for CM-AT, which has received Fast Track status from the FDA.  If approved, it will be one of the first therapies to address the underlying physiology of autism.          

Curemark's presentation is part of the 12th annual healthcare conference, an industry track that will be showcased during the Rodman & Renshaw Annual Global Investment Conference.  In addition to healthcare, the conference will highlight industry tracks including China, metals and mining, energy, technology, cleantech, community and regional banks, and REITs.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Opens Autism Trials at New Jersey Site
2. Curemark Begins Autism Trials at Two More Sites
3. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
4. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
5. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
9. Curemark Announces Senior Executive Promotions
10. Curemark CEO Presents at Epigenomics Conference
11. Curemark Closes Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 2016 --> ... "Fetal (Labor & Delivery) and Neonatal Care Equipment Market ... Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, & Resuscitator) - ... studies the global market over the forecast period of ... 6.28 Billion in 2015 and is poised to grow ...
(Date:2/4/2016)... , Feb. 4, 2016 For hospitals ... or those already participating in the program, the Health ... referred to as the , Mega-Guidance , could have ... guidance is published in September 2016. Essential ... and Service Marketing , summarizes the Mega-Guidance,s key proposed ...
(Date:2/4/2016)... CITY, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company") today announced it has entered into a ... Exchange Commission (SEC) fully resolving the SEC,s investigation ... Act (FCPA).  Under the terms of the settlement ... of $12.8 million, including disgorgement, pre-judgment interest and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The American public tends to ... may be safer than regular municipal or well water. The recent experience with lead ... Kleyne, could go a long way toward increasing public acceptance of recycled waste water ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held last week, ... of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. ... Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served APDA since ...
(Date:2/5/2016)... ... 05, 2016 , ... In sleep, when the defenses of the day are ... of patients with eating disorders is significant self-criticism, and consequently these patients experience this ... regarded as maladaptive means for coping with this unease, but also leads to a ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( http://www.kicventures.com ) ... event in New York City on Thursday, January 21, 2016. Kingsley R. ... (both alumnus of the varsity Columbia soccer program) spoke at the event, offering ...
(Date:2/4/2016)... ... February 04, 2016 , ... According to a recent ... see their dentist once every six months for a cleaning and checkup, depending on ... Dr. Farzad Feiz, head dentist at Calabasas Dental Group and California Dental Care, notes ...
Breaking Medicine News(10 mins):